Advertisement

Pervasis Therapeutics Inc. of Cambridge said it is expanding into oncology and considering additional financing from either a corporate partner or the venture capital community.

The company, which has focused on endothelial cell-based therapies for vascular surgeries or procedures, has entered into an exclusive patent license agreement with MIT so it can develop a novel, cell-based therapy to help prevent tumor growth and the spread of cancer cells.

SOURCE

Advertisement
Advertisement